专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明授权

EP2970385B1 COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF 有权转让
公开(公告)号：EP2970385B1
公开(公告)日：2018-10-03
申请号：EP14762306.0
申请日：2014-03-14
申请人： Shenzhen Hightide Biopharmaceutical, Ltd.
发明人： LIU, Liping , BAI, Ru
IPC分类号： C07K7/08 , C07K7/02 , A61K38/10 , A61P3/10
CPC分类号： C07K14/475 , A61K38/00 , C07K7/02 , C07K7/08 , C07K14/4705 , C07K14/4733 , C07K14/4738
摘要： The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.

3. 发明公开

EP3338790A3 OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF 有权转让
公开(公告)号：EP3338790A3
公开(公告)日：2018-07-11
申请号：EP18155330.6
申请日：2009-02-20
申请人： APIM Therapeutics AS
发明人： OTTERLEI, Marit , AAS, Per Arne , FEYZI, Emadoldin
IPC分类号： A61K38/17 , A61K38/16 , A61K38/46 , C07K14/47 , G01N33/68 , C12N15/12
CPC分类号： A61K38/1709 , A61K38/00 , A61K38/16 , A61K38/46 , A61K45/06 , C07K14/00 , C07K14/4738 , C07K2319/10 , C12Y306/03044 , G01N33/6872 , G01N33/6893 , G01N2800/56
摘要： The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in treatment of a hyperproliferative disorder,
wherein the PCNA interacting motif is
[R/K]-[W/F/Y]-[L/I/V/A/M]-[V/L/I/A/M]-[K/R] (SEQ ID NO. 28),
wherein the oligopeptidic compound has less than 70 subunits and comprises a cell penetrating peptide comprising an oligomer of 5 to 20 basic amino acids. In certain aspects the compounds of the invention may be used as cytostatic agents in their own right. In other aspects of the invention oligopeptidic compounds comprising such a motif may be used in conjunction with cytostatic agents or with radiotherapy.

4. 发明授权

EP3018202B1 E2EPF Ubiquitin carrier protein-von-Hippel-Lindau interaction and uses of thereof 有权
公开(公告)号：EP3018202B1
公开(公告)日：2018-06-27
申请号：EP15158221.0
申请日：2006-11-13
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： Im, Dong-Soo , Jung, Cho-Rok , Hwang, Kyung-Sun , Jung Hwa, Lim
IPC分类号： C12N9/00 , A61K38/53 , A61P9/10
CPC分类号： C12N9/93 , C07K14/4703 , C07K14/4738 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12Y603/02019
摘要： The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-la which enhances VEGF activation based on the HIF-1± stabilization. The method for regulating UCP activity or level results in the increase or decrease of VHL activity or level, so that it can be applied to the development of an anticancer agent and an angiogenesis inducer.

5. 发明公开

EP3178839A4 CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME 无效转让
公开(公告)号：EP3178839A4
公开(公告)日：2018-06-20
申请号：EP15830292
申请日：2015-07-31
申请人： ONCOTHERAPY SCIENCE INC
发明人： TSUNODA TAKUYA , OSAWA RYUJI , YAMASHITA SACHIKO , WATANABE TOMOHISA
IPC分类号： C07K7/06 , A61K35/12 , A61K35/14 , A61K38/00 , A61K39/395 , A61K48/00 , C07K7/08 , C07K16/28 , C12N5/10 , C12N15/09
CPC分类号： C07K14/4738 , A61K35/12 , A61K35/14 , A61K38/00 , A61K39/0011 , A61K39/395 , A61K48/00 , A61K2039/5154 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K16/18 , C07K16/28 , C12N5/10 , C12N15/09 , G01N33/505 , G01N33/574 , G01N2333/47
摘要： The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

6. 发明公开

EP3257943A3 METHODS AND VECTORS FOR CELL IMMORTALISATION 有权
公开(公告)号：EP3257943A3
公开(公告)日：2018-01-10
申请号：EP17180843.9
申请日：2011-11-02
申请人： Helmholtz-Zentrum für Infektionsforschung GmbH
发明人： MAY, Tobias , HAUSER, Hansjörg , SCHULLER, Franziska , ZAUERS, Jeannette , SCHUCHT, Roland
IPC分类号： C12N15/12 , C12N15/86 , C12N5/10 , C07K14/47 , C07K14/82 , A61K38/00 , A61K38/17
CPC分类号： C12N5/067 , A61K38/00 , C07K14/47 , C07K14/4738 , C07K14/82 , C12N5/00 , C12N5/0602 , C12N2501/155 , C12N2510/04 , C12N2740/15043
摘要： The present invention relates to a method and to vectors for the immortalisation of cells independent of their type. It further relates to a cell or a cell line produced with the method or the vectors of the invention. The invention also relates to the use of this cell or cell line in in vitro applications and in the treatment of disease.

7. 发明公开

EP3096770A1 MODULATION OF CELLULAR LOCALIZATION OF CYCLIN C 审中-公开
标题翻译：调制DELLZELLULÄRENLOKALISIERUNG VON CYCLIN C
公开(公告)号：EP3096770A1
公开(公告)日：2016-11-30
申请号：EP15737219.4
申请日：2015-01-16
申请人： Rowan University
发明人： STRICH, Randy , COOPER, Katrina
IPC分类号： A61K38/08
CPC分类号： A61K38/1709 , A61K45/06 , C07K14/4738 , C07K2319/03 , C12N7/00 , C12N2740/16311 , C12N2740/16322 , G01N33/5011
摘要： Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include a compound that induces the translocation of cyclin C from the cell nucleus to the cytoplasm. Also provided are methods of screening tumor cells for susceptibility to compounds that induce the translocation of cyclin C.
摘要翻译：提供用于治疗癌症的方法和组合物。特别地，这些方法和组合物可以包括诱导细胞周期蛋白C从细胞核转移到细胞质的化合物。还提供筛选肿瘤细胞对诱导细胞周期蛋白C易位的化合物的敏感性的方法。

8. 发明公开

EP3018202A1 E2EPF Ubiquitin carrier protein-von-Hippel-Lindau interaction and uses of thereof 有权
标题翻译： E2EPF-Ubiquitinträger-Protein-von-Hippel-Lindau-Interaktion und Verwendungen davon
公开(公告)号：EP3018202A1
公开(公告)日：2016-05-11
申请号：EP15158221.0
申请日：2006-11-13
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： Im, Dong-Soo , Jung, Cho-Rok , Hwang, Kyung-Sun , Jung Hwa, Lim
IPC分类号： C12N9/00 , A61K38/53 , A61P9/10
CPC分类号： C12N9/93 , C07K14/4703 , C07K14/4738 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12Y603/02019
摘要： The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-la which enhances VEGF activation based on the HIF-1α stabilization. The method for regulating UCP activity or level results in the increase or decrease of VHL activity or level, so that it can be applied to the development of an anticancer agent and an angiogenesis inducer.
摘要翻译：本发明涉及E2EPF UCP-VHL相互作用及其用途，更确切地说，涉及通过调节UCP活性或抑制癌细胞增殖或转移或增加血管生成的水平来增加或降低VHL活性或水平的方法。 UCP活性的抑制是通过选自小干扰RNA（RNAi），反义寡核苷酸和与UCP mRNA，肽，模拟物和抗体互补结合的多核苷酸的任何UCP活性抑制剂完成的，和低分子化合物。同时，通过以下机制实现血管生成的增加; UCP过表达由基因载体诱导，因此内源性VHL被降低，导致HIF-1a的稳定化，其基于HIF-1±稳定增强VEGF活化。调节UCP活性或水平的方法导致VHL活性或水平的增加或降低，从而可以应用于抗癌剂和血管生成诱导剂的开发。

9. 发明公开

EP2742133A4 MPHOSPH1 PEPTIDES AND VACCINES INCLUDING THE SAME 有权
标题翻译： MPHOSPH1-PEPTIDE UNDESE ENTHALTENDE IMPFSTOFFE
公开(公告)号：EP2742133A4
公开(公告)日：2015-07-01
申请号：EP12824137
申请日：2012-08-09
申请人： ONCOTHERAPY SCIENCE INC
发明人： TSUNODA TAKUYA , OSAWA RYUJI , YOSHIMURA SACHIKO , WATANABE TOMOHISA , NAKAMURA YUSUKE
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , A61P43/00 , C07K7/06
CPC分类号： C12N9/93 , A61K38/00 , A61K39/00 , A61K39/0011 , C07K14/4738 , C12N5/0639 , C12N5/10 , C12N9/14 , C12N2502/1114 , C12Y306/04004 , G01N33/505 , G01N33/57407 , G01N2440/14

10. 发明公开

EP2857035A1 Survivin-derived peptides and use thereof 有权
标题翻译：来自存活蛋白的肽及其用途
公开(公告)号：EP2857035A1
公开(公告)日：2015-04-08
申请号：EP14191677.5
申请日：2004-01-30
申请人： Survac ApS
发明人： Straten, Eivind Per Thor , Andersen, Mads Hald
IPC分类号： A61K38/17 , A61P35/00 , C07K14/47 , C07K16/18 , G01N33/574 , G01N33/68 , A61K39/00
CPC分类号： C07K14/4747 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , C07K14/4738 , G01N33/574 , G01N33/57484
摘要： MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof. The specific peptide is Sur6-14, LPPAWQPFL.
摘要翻译：衍生自肿瘤相关抗原的存活蛋白的MHC I类限制性肽，所述肽能够以高亲和力与I类HLA分子结合，能够引发癌症患者的PBL群体中产生IFN-γ的细胞，并且能够原位检测肿瘤组织中的细胞毒性T细胞，包含该肽的治疗和诊断组合物及其用途。特定的肽是Sur6-14，LPPAWQPFL。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式